1. Home
  2. BEAT vs KZR Comparison

BEAT vs KZR Comparison

Compare BEAT & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.88

Market Cap

53.2M

Sector

Technology

ML Signal

HOLD

Logo Kezar Life Sciences Inc.

KZR

Kezar Life Sciences Inc.

HOLD

Current Price

$7.29

Market Cap

54.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
KZR
Founded
2015
2015
Country
United States
United States
Employees
16
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.2M
54.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BEAT
KZR
Price
$0.88
$7.29
Analyst Decision
Strong Buy
Hold
Analyst Count
4
4
Target Price
$5.63
$6.00
AVG Volume (30 Days)
610.9K
118.8K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$315.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$3.53
52 Week High
$4.00
$7.55

Technical Indicators

Market Signals
Indicator
BEAT
KZR
Relative Strength Index (RSI) 41.90 54.64
Support Level $0.81 $7.25
Resistance Level $1.28 $7.47
Average True Range (ATR) 0.07 0.11
MACD 0.00 -0.02
Stochastic Oscillator 5.62 37.50

Price Performance

Historical Comparison
BEAT
KZR

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Share on Social Networks: